Physician profile
Eric J Lehman
NPI 1164464046
$879.36
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $56.02 · 2022: $102 · 2023: $277 · 2024: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.57 | 2023-2024 | |
| Novo Nordisk INC | $107.06 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $104.19 | 2019-2024 | |
| Exact Sciences Corporation | $77.82 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $53.46 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $52.40 | 2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $37.66 | 2022-2023 | Bexsero, Shingrix, Arexvy |
| Amarin Pharma, INC. | $28.55 | 2019-2020 | |
| Inspire Medical Systems, INC. | $22.06 | 2024 | Inspire |
| Neurocrine Biosciences, INC. | $18.86 | 2024 | Ingrezza |
| Vertex Pharmaceuticals Incorporated | $18.79 | 2024 | |
| Amgen INC. | $17.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.24 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $16.74 | 2019 | |
| Becton, Dickinson and Company | $16.16 | 2024 | Bd Max System, Bd Max Instrument |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.